Trial · NCT03305809
A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
NCT03305809, Phase 2, Completed, Eli Lilly and Company; results first posted 2021-07-23
3 sourcestrials-2026-11-12-0.4.0
Download JSON
Cite this record
ConductScience Library. A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB). Trials, record NCT03305809. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03305809
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
- NCT number
- NCT03305809
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 344 participants, actual
- Lead sponsor
- Eli Lilly and Company
- Conditions
- Lewy Body Dementia
- Interventions
- LY3154207, Placebo
- First posted
- 2017-10-10
- Last updated
- 2021-07-23
- Results first posted
- 2021-07-23
Source ClinicalTrials.gov
Registered outcomes20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change From Baseline in the Continuity of Attention (CoA) Composite Score of the Cognitive Drug Research Computerized Cognition Battery (CDR-CCB) | Baseline, Week 12 | The CDR-CCB tests is designed to evaluate the effects of novel compounds on the quality of cognitive functioning which includes tests of attention (simple and choice reaction time, digit vigilance), working memory (spatial and numeric) and episodic memory (word recognition, picture recognition). Continuity of attention measures speed and accuracy and is calculated from 3 attentional tasks on the CDR computerized battery tests. For continuity of attention, the score range is -999 to 35. A high score reflects someone able to keep his/her mind on a single task for a prolonged period. A negative change from baseline reflects impairment compared to baseline. Data presented are model-based bayesian posterior mean response rates with 95% credible interval. |
| Secondary | Change From Baseline on the Alzheimer's Disease Cooperative Study-Clinician Global Impression of Change (ADCS-CGIC) Score | Baseline, Week 12 | The ADCS-CGIC is a validated categorical measure of change in a participant's clinical condition between baseline and follow-up visits; it is used to assess global clinical status. The ADCS CGIC score is based on direct examination of the participant and an interview of the caregiver. The rater should refer to the baseline ADCS-CGIC worksheets in making a rating. A skilled and experienced clinician who is blinded to treatment assignment rates the participant on a 7-point Likert scale, ranging from 1 (marked improvement) to 7 (marked worsening). 1= Very much better 2= Much better 3= A little better 4= Same 5= A little worse 6= Much worse 7= Very much worse. Least squares (LS) means were calculated using mixed model repeated measures adjusting for treatment + visit + treatment\*visit + age\*acheifl + age + concomitant use of acetylcholinesterase inhibitor (AChEI). |
| Secondary | Change From Baseline on the CDR-CCB Power of Attention (PoA) Composite Score | Baseline, Week 12 | The PoA is a composite score derived from the CDR-CCB that measures the intensity of concentration (ability to focus attention): the faster the responses, the more processes are being brought to bear upon the task. Power of attention is calculated from the sum of three cognitive function speed tests: simple reaction time, choice reaction time and the speed of detections in digit vigilance task. Score ranges from 450 milliseconds - 61500 milliseconds. A low score reflects a fast reaction time and a high intensity of concentration. A positive change from baseline reflects impairment compared to the baseline assessment Values are calculated by a computer and higher scores mean better outcome. LS means were calculated using mixed model repeated measures adjusting for baseline total Score + treatment + visit + treatment\*Visit + visit\*baseline total Score + age + concomitant use of AChEI. |
| Secondary | Change From Baseline in the 13-item Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog13) | Baseline, Week 12 | The ADAS is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS that was used as the primary efficacy measure consists of 13 items assessing areas of cognitive function most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, digit cancellation. The ADAS--Cog13 scale ranges from 0 to 85. Higher scores indicate greater disease severity. LS means were calculated using mixed model repeated measures adjusting for baseline total Score + treatment + visit + treatment\*Visit + visit\*baseline total Score + age + concomitant use of AChEI. |
| Secondary | Change From Screening in the Montreal Cognitive Assessment (MoCA) Score | Screening (Baseline), Week 12 | The Montreal Cognitive Assessment is a screening tool for global cognitive function with a total score ranging from 0 to 30 units on a scale. The MoCA is divided into 7 subscores (maximum possible subscore): visuospatial/executive (5 points), naming (3 points), memory (5 points for delayed recall), attention (6 points), language (3 points), abstraction (2 points) and orientation to time and place (6 points). A score of 26-30 is normal. A score less than 26 is considered as mild cognitive impairment. Higher values represent a better outcome. LS means were calculated using mixed model repeated measures adjusting for baseline total Score + treatment + visit + treatment\*Visit + visit\*baseline total Score + age + concomitant use of AChEI. |
| Secondary | Change From Baseline in the Neuropsychiatric Inventory (NPI) Total Score and Individual Item Scores | Baseline, Week 12 | The NPI is a condition-specific measure designed to assess neuropsychiatric disturbances in people with Alzheimer Disease (AD),as well as other related dementing disorders.It assesses 12 behavioral disturbances,namely delusions,hallucinations,depression/dysphoria,anxiety,agitation/aggression,elation/euphoria,disinhibition,irritability/lability,apathy, aberrant motor activity, night-time behavior disturbances,and appetite/eating abnormalities.The frequency scored from 0 (never) to 4 (very frequently).The Severity scored from 0 (none) to 3 (marked).The domain score is obtained by multiplying frequency and severity scores.The total NPI score is sum total of all of individual domain scores (0-144).Higher score indiciates more abnormal behaviors.LS means were calculated using mixed model repeated measures adjusting for baseline total score + treatment + visit + treatment\*visit + visit\*baseline total score + age + concomitant use of AChEI. |
| Secondary | Change From Baseline in the Epworth Sleepiness Scale (ESS) Score | Baseline, Week 12 | The ESS is a self-administered questionnaire with 8 questions. Each activity is scored on a scale ranging from 0-3, with 0 = would never fall asleep, and 3 = high chance of falling asleep. The total score ranges from 0-24, with a higher number representing an increased propensity for sleepiness. LS means were calculated using mixed model repeated measures adjusting for baseline total score + treatment + visit + treatment\*visit + visit\*baseline total score + age + concomitant use of AChEI. |
| Secondary | Change From Baseline in the Movement Disorder Society's Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Total Score (Sum of Parts I-III) | Baseline, Week 12 | Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) retains the four-scale structure with a reorganization of the various subscale; (Part I; 13 items) non-motor experiences of daily living, (Part II; 13) motor experiences of daily living, (Part III; 34) motor examination, and (Part IV; 6) motor complications. The scale range for MDS-UPDRS MDS-UPDRS Part I (non-motor experiences of daily living) and Part II (motor experiences of daily living) scores, total score was 0-52, with higher scores reflecting greater severity. For MDS-UPDRS Part III (motor examination) scores, the scale range for Part III Total Score was 0-132, with higher scores reflecting greater severity. LS means were calculated using mixed model repeated measures adjusting for baseline total score + treatment + visit + treatment\*visit + visit\*baseline total score + age + concomitant use of AChEI + levodopa equivalency dose (LED). |
| Secondary | Change From Baseline in the Penn Parkinson's Daily Activities Questionnaire-15 (PDAQ-15) Total Score | Baseline, Week 12 | The PDAQ-15 is a 15-item measure of instrumental activities of daily living (IADL) that are impacted by cognitive impairment in participants with parkinson's disease dementia (PDD). The PDAQ-15 is derived from the original 50-item scale, which has demonstrated test-retest reliability, construct validity, sensitivity, and specificity to Parkinson's disease (PD) cognitive impairment and the questionnaire is completed by the caregiver. The score range is 0 to 60, with higher scores indicating better function. LS means were calculated using mixed model repeated measures adjusting for baseline total score + treatment + visit + treatment\*visit + visit\*baseline total score + age + concomitant use of AChEI. |
| Secondary | Change From Baseline in Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency Test Score | Baseline, Week 12 | The DKEFS verbal fluency category switching test measures letter fluency, category fluency, and category switching. The score is the total number of correct words generated during each of the 60-second trials within the three conditions of the test. Scales scores vary from 0 min to N/A max (no concrete maximum). Higher score = higher ability in language processing. LS means were calculated using mixed model repeated measures adjusting for baseline total score + treatment + visit + treatment\*visit + visit\*baseline total score + age + concomitant use of AChEI. |
1 to 10 of 20Source ClinicalTrials.gov
See all 20 registered outcomesOutcomes20
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline in the Continuity of Attention (CoA) Composite Score of the Cognitive Drug Research Computerized Cognition Battery (CDR-CCB) | Baseline, Week 12 | All randomized participants who received at least 1 dose of study drug, who had the baseline efficacy assessment and had at least 1 postdose efficacy assessment. | Units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline on the Alzheimer's Disease Cooperative Study-Clinician Global Impression of Change (ADCS-CGIC) Score | Baseline, Week 12 | All randomized participants who received at least one dose of study drug with baseline and post-baseline CGIC data. | Score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline on the CDR-CCB Power of Attention (PoA) Composite Score | Baseline, Week 12 | All randomized participants who received at least one dose of study drug with baseline and post-baseline CDR-CCB PoA data. | Units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in the 13-item Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog13) | Baseline, Week 12 | All randomized participants who received at least one dose of study drug with baseline and post-baseline ADAS-Cog13 data. | Units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Screening in the Montreal Cognitive Assessment (MoCA) Score | Screening (Baseline), Week 12 | All randomized participants who received at least one dose of study drug with baseline and post-baseline MoCA data. | Units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in the Neuropsychiatric Inventory (NPI) Total Score and Individual Item Scores | Baseline, Week 12 | All randomized participants who received at least one dose of study drug with baseline and post-baseline NPI score data. | Units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in the Epworth Sleepiness Scale (ESS) Score | Baseline, Week 12 | All randomized participants who received at least one dose of study drug with baseline and post-baseline ESS data. | Units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in the Movement Disorder Society's Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Total Score (Sum of Parts I-III) | Baseline, Week 12 | All randomized participants who received at least one dose of study drug with baseline and post-baseline MDS-UPDRS data. | Units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in the Penn Parkinson's Daily Activities Questionnaire-15 (PDAQ-15) Total Score | Baseline, Week 12 | All randomized participants who received at least one dose of study drug with baseline and post-baseline PDAQ-15 data. | Units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency Test Score | Baseline, Week 12 | All randomized participants who received at least one dose of study drug with baseline and post-baseline D-KEFS data. | Units on a scale | LEAST_SQUARES_MEAN |
1 to 10 of 20Source ClinicalTrials.gov
See all 20 outcomesResults by group159
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in the Continuity of Attention (CoA) Composite Score of the Cognitive Drug Research Computerized Cognition Battery (CDR-CCB) | Placebo | 1.04 | 95% Confidence Interval -0.339 to 2.373 | Units on a scale | |
| Change From Baseline in the Continuity of Attention (CoA) Composite Score of the Cognitive Drug Research Computerized Cognition Battery (CDR-CCB) | 10 mg LY3154207 | 0.15 | 95% Confidence Interval -1.206 to 1.496 | Units on a scale | |
| Change From Baseline in the Continuity of Attention (CoA) Composite Score of the Cognitive Drug Research Computerized Cognition Battery (CDR-CCB) | 30 mg LY3154207 | 0.96 | 95% Confidence Interval -0.448 to 2.362 | Units on a scale | |
| Change From Baseline in the Continuity of Attention (CoA) Composite Score of the Cognitive Drug Research Computerized Cognition Battery (CDR-CCB) | 75 mg LY3154207 | 0.26 | 95% Confidence Interval -1.310 to 1.801 | Units on a scale | |
| Change From Baseline on the Alzheimer's Disease Cooperative Study-Clinician Global Impression of Change (ADCS-CGIC) Score | Placebo | 4.0 | Standard Error 0.13 | Score on a scale | |
| Change From Baseline on the Alzheimer's Disease Cooperative Study-Clinician Global Impression of Change (ADCS-CGIC) Score | 10 mg LY3154207 | 3.8 | Standard Error 0.12 | Score on a scale | |
| Change From Baseline on the Alzheimer's Disease Cooperative Study-Clinician Global Impression of Change (ADCS-CGIC) Score | 30 mg LY3154207 | 3.3 | Standard Error 0.13 | Score on a scale | |
| Change From Baseline on the Alzheimer's Disease Cooperative Study-Clinician Global Impression of Change (ADCS-CGIC) Score | 75 mg LY3154207 | 3.1 | Standard Error 0.15 | Score on a scale | |
| Change From Baseline on the CDR-CCB Power of Attention (PoA) Composite Score | Placebo | 64.14 | Standard Error 48.681 | Units on a scale | |
| Change From Baseline on the CDR-CCB Power of Attention (PoA) Composite Score | 10 mg LY3154207 | -6.57 | Standard Error 48.396 | Units on a scale |
1 to 10 of 159Source ClinicalTrials.gov
See all 159 results by groupParticipant flow16
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Placebo | 86 | |
| Overall Study | STARTED | 10 Milligram (mg) LY3154207 | 86 | |
| Overall Study | STARTED | 30 mg LY3154207 | 85 | |
| Overall Study | STARTED | 75 mg LY3154207 | 87 | |
| Overall Study | Received at Least One Dose of Study Drug | Placebo | 86 | |
| Overall Study | Received at Least One Dose of Study Drug | 10 Milligram (mg) LY3154207 | 86 | |
| Overall Study | Received at Least One Dose of Study Drug | 30 mg LY3154207 | 85 | |
| Overall Study | Received at Least One Dose of Study Drug | 75 mg LY3154207 | 87 | |
| Overall Study | COMPLETED | Placebo | 79 | |
| Overall Study | COMPLETED | 10 Milligram (mg) LY3154207 | 78 |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 participant flowAdverse events160
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Diarrhoea | Gastrointestinal disorders | Placebo | 1 | 86 | 1 |
| other | Diarrhoea | Gastrointestinal disorders | 10 mg LY3154207 | 2 | 86 | 2 |
| other | Diarrhoea | Gastrointestinal disorders | 30 mg LY3154207 | 5 | 85 | 7 |
| other | Diarrhoea | Gastrointestinal disorders | 75 mg LY3154207 | 2 | 87 | 4 |
| other | Nausea | Gastrointestinal disorders | Placebo | 3 | 86 | 5 |
| other | Nausea | Gastrointestinal disorders | 10 mg LY3154207 | 2 | 86 | 2 |
| other | Nausea | Gastrointestinal disorders | 30 mg LY3154207 | 7 | 85 | 8 |
| other | Nausea | Gastrointestinal disorders | 75 mg LY3154207 | 8 | 87 | 9 |
| other | Vomiting | Gastrointestinal disorders | Placebo | 3 | 86 | 3 |
| other | Vomiting | Gastrointestinal disorders | 10 mg LY3154207 | 0 | 86 | 0 |
1 to 10 of 160Source ClinicalTrials.gov
See all 160 adverse eventsAdverse event totals12
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Placebo | 0 | 86 |
| Total, all-cause mortality | 10 mg LY3154207 | 0 | 86 |
| Total, all-cause mortality | 30 mg LY3154207 | 1 | 85 |
| Total, all-cause mortality | 75 mg LY3154207 | 1 | 87 |
| Total, other adverse events | Placebo | 20 | 86 |
| Total, other adverse events | 10 mg LY3154207 | 26 | 86 |
| Total, other adverse events | 30 mg LY3154207 | 30 | 85 |
| Total, other adverse events | 75 mg LY3154207 | 43 | 87 |
| Total, serious adverse events | Placebo | 3 | 86 |
| Total, serious adverse events | 10 mg LY3154207 | 5 | 86 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse event totalsPapers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests6
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Choice Reaction Time | Primary outcome | ConductCognition |
| Cancellation Test | Secondary outcome | ConductCognition |
| Category Fluency | Secondary outcome | ConductCognition |
| Delayed Recall Module | Secondary outcome | ConductCognition |
| Simple Reaction Time | Secondary outcome | ConductCognition |
| Verbal Fluency | Secondary outcome | ConductCognition |
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03305809
GET https://conductscience.org/api/trials/v1/NCT03305809/results?page=2